Neuromuscular Disorders

Immunotherapy for Neuromuscular Disorders and Infection Risk

Infection Rate Following Immunotherapy for Neuromuscular Disorders

2015 – 2020

Immunotherapy is the most effective treatment for a number of neuromuscular disorders, including inflammatory myopathy, myasthenia gravis, Lambert-Eaton myasthenic syndrome, and chronic inflammatory demyelinating polyneuropathy. Commonly used treatments may include corticosteroids, azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, rituximab, intravenous immunoglobulin, and plasmapheresis. While effective, these treatments can weaken the immune system, leading to complications of infection. At times, resulting infections are severe, requiring hospitalization. Balancing the efficacy of treatment and the risk of infection is often the key in the successful treatment of immune-mediated neuromuscular disorders.

Between 2015 and 2020, the Neuromuscular Center has administrated immunotherapy to > 3000 patients with a variety of neuromuscular disorders while keeping the incidence of significant infection low (< 10%) for all 6 years. N = total number of patients being treated with immunotherapy for long duration.